About the Adorable1 Study
If your child or young loved one has been diagnosed with atopic dermatitis (eczema), they may be eligible to participate in a new, phase III clinical research study. The purpose of this trial is to determine if a new investigational option called lebrikizumab is safe and effective in treating atopic dermatitis in children. Approximately 300 children will be recruited for this study. Children who successfully enroll in this study will be asked to participate for up to 30 weeks including screening, study drug administration, and follow-up periods. During this 30-week time frame, participants will also be asked to visit the study site approximately 11 times for planned study procedures. Certain patients may require more visits as needed.
Participants who successfully enroll in the study will be assigned by random chance to receive lebrikizumab or placebo during the study. The placebo looks like the active investigational drug, though it does not contain any active drug. During the study, lebrikizumab or a placebo will be provided to the child once every 2 weeks or once every 4 weeks.
Study Criteria
To participate in this study, children must*:
- Be 6 - <18 years of age
- Be clinically diagnosed with atopic dermatitis, also known as eczema, for at least one year
- Have a poor or unsatisfactory response using certain topical medications
Other criteria for eligibility apply. Study participants receive study-related medical exams and investigational drug at no cost. Compensation for time and travel may be available.*
Refer A Friend
Do you know someone ages 6 – < 18 who has eczema? They may be eligible to participate in the study. Consider sharing information with them about how they can learn more.